Schizophrenia Flashcards
1
Q
Schizophrenia pearls
A
- Age 20-30 onset
- Same prevalence worldwide
- PANSS scale for mental status
- Patient hx is important to rule out other conditions (drug-induced, comorbidity-induced)
2
Q
When should clozapine be considered?
A
- Treatment-resistant patients
- Substantial risk of, or attempted suicide
3
Q
T/F: SGA and FGA can be mixed without issues
A
F: FGA can negate efficacy of SGA
4
Q
FGA Side Effects
A
- EPS
- QTc prolongation
- Prolactin elevation
- Dermatologic
- Photosensitivity
- Blue/gray skin
- Orthostatic HTN
- Altered thermoregulation
5
Q
FGA BBW
A
Dementia-related psychosis -> do not use, increased risk of CV death
6
Q
SGA Side Effects
A
- Metabolic syndrome (Hypergly, hypertri, weight gain)
- QTc prolongation
- Blood dyscrasia/neutropenias
- Seizure threshold
- Anticholinergic
- Sedation
- Prolactin elevation
- Ophthalmic effects
7
Q
SGA BBW
A
Dementia-related psychosis
8
Q
Which SGA is approved for agitation in Alzheimer’s?
A
Brexpiprazole
9
Q
Which is the ONLY SGA not approved for schizophrenia?
A
Pimevanserin
10
Q
Which SGAs are approved for MDD augmentation?
A
- Aripiprazole
- Brexpiprazole
- Olanzapine (ONLY with fluoxetine)
- Quetiapine
11
Q
Aripiprazole
A
- Less sedating -> insomnia, akathisia, restlessness
- Impulsivity
Available as tablet, solution, Mycite, Initio injection, LAI
12
Q
Asenapine
A
- Less weight gain
- Less sedating/anticholinergic
- Do not drink/eat 10 min after SL
- CI in hepatic disease
- High QTc risk
- Monitor for anaphylaxis after 1st dose
- Skin site reactions, do not apply heat to patch
Available as SL, topical patch
13
Q
Brexpiprazole
A
- Long t1/2 (91h)
- Akathisia reported (dose related)
- Less metabolic ADEs
- Impulsivity
Available as oral tablet
14
Q
Cariprazine pearls
A
- Long t1/2 (91h) and metabolites contribute to late ADEs (accumulation)
- Akathisia (dose related)
- Less metabolic ADEs
Available as oral capsule
15
Q
Clozapine
A
- Gold standard for refractory/suicide risk
- Metabolic risks (greatest)
- BBW blood dyscrasias (REMS) - dose-independent
- QTc, bradycardia
- Myocarditis
- Seizure with high conc.
- Anticholinergic -> very constipating (can be fatal)
- Hypersalivation
- Hepatotoxicity, fever, PE, anticholinergic toxicity
- Dose interruption >48h needs re-titration
- Respiratory depression with benzos
- Clozapine + carbamazepine = low ANC
- Must trial 2 other drugs before starting
Available oral tablet, ODT, suspension
16
Q
Iloperidone
A
- Orthostatic HTN
- Priapism
- QTc, less sedation
- Avoid in hepatic impairment
- Slow titration
- Not really used
Available as oral tablet
17
Q
Lurasidone
A
- Neuro ADRs in dementia/PD
- No notable metabolic SE or EPS
- Sedation
Available as oral capsule
18
Q
Olanzapine
A
- Second worst for metabolic risk
- FDA BBW post-injection delirium/sedation (REMS) with LAI
- DRESS
- QTc
- anticholinergic
- Respiratory depression with benzos
Available as oral tablet, ODT, short acting IM, LAI
19
Q
Olanzapine + samidorphan
A
- Risk of opioid withdrawal if dependent/using
- Samidorphan is to mitigate metabolic effects of olanzapine
20
Q
Paliperidone
A
- QTc
- GI obstruction
- Priapism
- Metabolite of risperidone -> similar ADE
- Thrombotic thrombocytopenic
purpura, antiemetic effects
Available as oral tablet, LAI